The suppressed expression level of FAM65A was observed in esophageal cancer, kidney cancer, lung cancer and ovarian cancer, while elevated expression level of FAM65A was observed in colorectal cancer, compared with the control (Fig. 1b). Here, RIPOR1 is linked to ovarian cancer.